{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
dimethyl fumarate
to a specific field?
Status:
Investigational
Source:
INN:bioresmethrin [INN]
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Conditions:
Bioresmethrin is a synthetic pyrethroid insecticide. It is the (+)-trans isomer of resmethrin which itself contains a minimum of 30% bioresmethrin. Bioresmethrin is the [1R, trans] isomer of resmethrin and has greater insecticidal activity than the racemic mixture. Bioresmethrin is a potent contact insecticide effective against a wide range of household insects, plant pests, grain pests and insects found in animal housing. It exhibits a high order of insecticidal activity, which when coupled with its excellent toxicological properties, makes it potentially one of the safest and most useful insecticides now being produced.
Status:
Investigational
Source:
NCT02612285: Phase 2 Interventional Terminated Cancer
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
SNX-5422 (also known as PF-04929113) is a synthetic, novel, small molecule Hsp90 inhibitor with potential antineoplastic activity. Hsp90 is a molecular chaperone that plays a key role in the conformational maturation of oncogenic signaling proteins, such as HER2/ERBB2, AKT, RAF1, BCR-ABL, and mutated p53, as well as many other molecules that are important in cell cycle regulation or immune responses. Inhibition of Hsp90 by SNX-2112 may result in the proteasome degradation of oncogenic client proteins, including HER2/ERBB2, and the inhibition of tumor cell proliferation. SNX-5422 is originally developed by Pfizer and Serenex, Inc., and the phase I clinical trials for it has been completed in the treatment of solid tumors. Although the mechanism of action remains to be fully elucidated, SNX-5422, which is a prodrug, is rapidly converted to SNX-2112 that accumulates in tumors relative to normal tissues.
Status:
Investigational
Source:
NCT01089738: Phase 1 Interventional Withdrawn Healthy
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
PF-03382792 is an oxindole derivative. PF-03382792 is highly potent and selective 5-HT4 partial agonist. It has excellent brain penetration properties. PF-03382792 increased acetylcholine release in the rat prefrontal cortex. It have been reported to reverse learning deficits induced by cholinergic agents. A safety assessment of this compound revealed large therapeutic margins between efficacious concentrations and safety findings. PF-03382792 reached human Phase I clinical trials but future development was discontinued.
Status:
Investigational
Source:
NCT01033487: Phase 2 Interventional Completed Pulmonary Disease, Chronic Obstructive
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
PF-03635659 is a potent, very long dissociative half-life (slow off-rate, >1440 min) muscarinic M3 antagonist. Spirometry data from healthy volunteers in phase I clinical studies illustrate that PF-03635659 provides efficacious 24 h bronchodilation from a single inhaled dose, thus confirming the suitability of PF-03635659 as a novel once-daily inhaled muscarinic M3 receptor antagonist for the treatment of chronic obstructive pulmonary disease (COPD). Safety (tachycardia) and toleration (dry mouth) data from the multidose phase I studies indicate an adverse event profile that is at least noninferior to tiotropium bromide. PF-03635659 had been in phase II clinical trial for the treatment of chronic obstructive pulmonary disease.
Status:
Investigational
Source:
NCT01517373: Phase 2 Interventional Completed Diabetes Mellitus, Type 2
(2012)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Status:
Investigational
Source:
NCT00932126: Phase 1 Interventional Terminated Advanced Solid Tumors
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
PF-3758309 was developed as an ATP-competitive inhibitor of PAK4. In cells, PF-3758309 inhibits phosphorylation of the PAK4 substrate GEF-H1 (IC50 = 1.3 nM) and anchorage-independent growth of a panel of tumor cell lines (IC50 = 4.7 nM). PF-3758309 blocks the growth of multiple human tumor xenografts, with a plasma EC50 value of 0.4 nM in the most sensitive model. PF-3758309 is antiproliferative and induces apoptosis in an HCT116 tumor model.
Status:
Investigational
Source:
NCT00800618: Phase 1 Interventional Completed Endometriosis
(2008)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
PF-02413873 is a selective nonsteroidal progesterone receptor (PR) antagonist. PF-02413873 is turned over by recombinant human P450s, with CYP3A4 displaying the highest turnover of those enzymes tested. PF-02413873 possessed low oral clearance in human with a pharmacokinetic profile consistent with a once-daily dosing schedule. The pharmacological mode of action of PF-02413873 seems to differ from the founding member of the class of steroidal PR antagonists RU-486. Exposure-effect data from studies in the cynomolgus macaque, however, demonstrated that PF-02413873 reduced endometrial functionalis thickness to a comparable degree to RU-486 and this effect was accompanied by a decrease in proliferation rate for both RU-486 and high-dose PF-02413873. PF-02413873blocked the follicular phase increase in endometrial thickness, the midcycle luteinizing hormone surge, and elevation in estradiol in a dose-dependent fashion compared with placebo. PF-02413873 had been in phase I clinical trial for the treatment of endometriosis. However, this development was discontinued.
Status:
Investigational
Source:
NCT03473925: Phase 2 Interventional Completed Solid Tumors
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Navarixin (SCH 527123) is an oral antagonist of CXC receptors 1 and 2. The drug is currently under Phase II trial for the treatment of psoriasis, COPD and asthma.
Status:
Class (Stereo):
CHEMICAL (ACHIRAL)
Emilium is an antiarrhythmic agent and cardiac depressant.
Status:
Investigational
Source:
NCT02554877: Phase 2 Interventional Completed Type 2 Diabetes Mellitus
(2015)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
